Hepatocellular carcinoma and direct- acting antivirals: A never ending story?

Hepatocellular carcinoma and direct- acting antivirals: A never ending story?
Vincenza Calvaruso* andAntonio Craxì Version of Record online: 24 MAY 2017 DOI: 10.1111/liv.13421

Liver International

Volume 37, Issue 6, pages 812–814, June 2017

Key Points

• The benefit of SVR is higher in patients without clinically significant portal hypertension

• HCC occurrence in patients with compensated cirrhosis is comparable to historical controls of patients who achieved SVR after interferon-based therapy.

• Patients who achieve SVR with DAAs had a lower risk of developing liver cancer than those patients whose HCV infection was not cured.

• Data available on patients with previous HCC do not show an increased risk of HCC recurrence and report a comparable rate of reappearance of cancer among DAA-treated and
 untreated patients.

Full Text

Download PDF

Link Provided By
Henry E. Chang via Twitter

May 26